Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)

Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)

Abstract Background Although chemotherapy for metastatic colorectal cancer (mCRC) has improved, the standard chemotherapy regimens for patients with RAS wild-type mCRC remain debated. This study aimed to compare S-1 and oxaliplatin (SOX) + bevacizumab (B-mab) with SOX + cetuximab (C-mab) in patients...

Full description

Bibliographic Details
Main Authors: Yujiro Nishizawa, Naotsugu Haraguchi, Hirotoshi Kim, Yoshihito Ide, Ken Nakata, Shu Okamura, Toshihiro Kudo, Taroh Satoh, Mamoru Uemura, Chu Matsuda, Tsunekazu Mizushima, Kohei Murata, Yuichiro Doki, Hidetoshi Eguchi
Format: Article
Language:English
Published: BMC 2021-08-01
Series:BMC Cancer
Subjects:
Cetuximab
Chemotherapy
Colorectal cancer
Early tumor shrinkage
KRAS
Oxaliplatin
Online Access:https://doi.org/10.1186/s12885-021-08690-y

Internet

https://doi.org/10.1186/s12885-021-08690-y

Similar Items